{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:47:34Z","timestamp":1762098454808},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/maj.0b013e31825b8edf","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T16:00:46Z","timestamp":1347552046000},"page":"343-348","source":"Crossref","is-referenced-by-count":18,"title":["Incidence of Musculoskeletal and Neoplastic Diseases in Patients on Statin Therapy: Results of a Retrospective Cohort Analysis"],"prefix":"10.1016","volume":"345","author":[{"given":"Ishak A.","family":"Mansi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0010","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0015","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0020","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0025","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0030","doi-asserted-by":"crossref","first-page":"11F","DOI":"10.1016\/j.amjcard.2005.06.008","article-title":"Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions","volume":"96","author":"Mason","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins\u2014mechanisms and consequences","volume":"4","author":"Beltowski","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2008.01.023","article-title":"The double-edged sword of statin immunomodulation","volume":"135","author":"Goldstein","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/art.23309","article-title":"Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature","volume":"59","author":"Marie","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ptsp.2009.01.003","article-title":"Simultaneous bilateral Achilles tendon ruptures associated with statin medication despite regular rock climbing exercise","volume":"10","author":"Carmont","year":"2009","journal-title":"Phys Ther Sport"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/FJC.0b013e3181a0ce8b","article-title":"Association between statin therapy and tendon rupture: a case-control study","volume":"53","author":"Beri","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjcard.2007.02.068","article-title":"Tendon rupture associated with simvastatin\/ezetimibe therapy","volume":"100","author":"Pullatt","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0065","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2008.06.037","article-title":"Statins, low-density lipoprotein cholesterol, and risk of cancer","volume":"52","author":"Alsheikh-Ali","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0070","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jacc.2008.06.036","article-title":"Statin treatment does not cause cancer","volume":"52","author":"Steinberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archpsyc.62.12.1305","article-title":"Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis","volume":"62","author":"Kemmler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-154-3-201102010-00007","article-title":"High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions","volume":"154","author":"Owens","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0085","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jacc.2009.12.057","article-title":"Earlier intervention in the management of hypercholesterolemia: what are we waiting for?","volume":"56","author":"Steinberg","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0090","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2009.11.090","article-title":"Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation\u2019s leading killer","volume":"56","author":"Forrester","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0095","series-title":"Military health system patient centered medical home guide: Tricare","author":"Kugler","year":"2011"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0100","series-title":"M2MHS Management Analysis and Reporting Tool Executive Information and Decision Support for the MHS","year":"2012"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0105","series-title":"Interface control document describing the case management exchange from BEA to MDR and M2 baseline","author":"Luhrman","year":"2008"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7205\/MILMED.173.5.434","article-title":"Analysis of weight and associated health consequences of the active duty staff at a major Naval medical center","volume":"173","author":"Gantt","year":"2008","journal-title":"Mil Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1741-7015-9-128","article-title":"Brief psychosocial education, not core stabilization, reduced incidence of low back pain: results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial","volume":"9","author":"George","year":"2011","journal-title":"BMC Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0120","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/jwh.2009.1706","article-title":"Oral contraceptive use among women in the military and the general U.S. population","volume":"19","author":"Enewold","year":"2010","journal-title":"J Womens Health"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0125","series-title":"Outpatient workload (RVU) predictors: age, gender & beneficiary category","author":"Moniz","year":"2008"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1097-0274(199602)29:2<171::AID-AJIM7>3.0.CO;2-V","article-title":"Lack of concordance between the ICD-9 classification of soft tissue disorders of the neck and upper limb and chart review diagnosis: one steel mill\u2019s experience","volume":"29","author":"Buchbinder","year":"1996","journal-title":"Am J Ind Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.atherosclerosis.2007.07.031","article-title":"The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+T cells","volume":"197","author":"Mausner-Fainberg","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5551\/jat.E551","article-title":"Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain","volume":"16","author":"Yu","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0155","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(04)15739-5","article-title":"Selenoprotein synthesis and side-effects of statins","volume":"363","author":"Moosmann","year":"2004","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0160","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2007.02.073","article-title":"Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials","volume":"50","author":"Alsheikh-Ali","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0170","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jacc.2008.08.001","article-title":"Low LDL-C levels and cancer reassuring but still not definitive","volume":"52","author":"Ben-Yehuda","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0895-4356(02)00614-5","article-title":"Statin use and the risk of breast cancer","volume":"56","author":"Beck","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.106.650176","article-title":"Statins and the risk of lung, breast, and colorectal cancer in the elderly","volume":"115","author":"Setoguchi","year":"2007","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jacc.2011.04.015","article-title":"Statins and risk of cancer: a retrospective cohort analysis of 45,857matched pairs from an electronic medical records database of 11 million adult Americans","volume":"58","author":"Marelli","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0190","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjmed.2007.12.011","article-title":"Statins and cancer risk","volume":"121","author":"Karp","year":"2008","journal-title":"Am J Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0195","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.108.824151","article-title":"Statin adherence and risk of accidents: a cautionary tale","volume":"119","author":"Dormuth","year":"2009","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0200","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0210","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0215","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0220","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0225","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0230","first-page":"7","article-title":"Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases","volume":"57","author":"Jordan","year":"2007","journal-title":"Br J Gen Pract"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0235","series-title":"A tale of two disability coding systems: the Veterans Administration Schedule for Rating Disabilities (VASRD) vs. Diagnostic Coding using the International Classification of Diseases","author":"Bell","year":"2008"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4065\/mcp.2009.0492","article-title":"An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy","volume":"85","author":"Caplan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0245","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/fampra\/6.2.92","article-title":"Morbidity coding in general practice","volume":"6","author":"Gray","year":"1989","journal-title":"Fam Pract"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0250","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31825b8edf_bb0255","series-title":"FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury","author":"Food and Drug Administration","year":"2011"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915306546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915306546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T21:03:28Z","timestamp":1562187808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915306546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0002962915306546"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31825b8edf","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}